Clinical Trial Update: Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating first-line combination therapy of sintilimab and anlotinib for advanced non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Carcinoma, Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN